Arctic Bioscience - Minutes of the Extraordinary General Meeting

19 Nov 2024 12:12 CET

An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 19
November 2024 at 10:00 (CET). All the items on the agenda were addressed and
approved. Attached is the minutes of the Extraordinary General Meeting.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

632616_20241119_ABS_Minutes_from_Extraord_General_Meeting_signert_.pdf